BioSpace News Archive

PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation at the American Association of Cancer Research (AACR) Annual Meeting 2023 being held from April 14-19 at the Orange County Convention Center in Orlando, Fla.

M2GEN , an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the American Association for Cancer Research (AACR) Annual Meeting April 14-19, 2023.

- Development of a novel antiviral drug against human papillomavirus

American Skin Association announced that James G. Krueger, MD, PhD, will join its Board of Directors.

Chinook Therapeutics, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 85,500 shares of common stock and restricted stock units for 44,580 shares with a grant date of March 31, 2023.

TherapeuticsMD, Inc. today reported financial results for the full year ended December 31, 2022.

A groundbreaking study by a team of scientists at YDS Pharmatech, Inc. has introduced an innovative Generative Diffusion Model for sampling ensembles of degrader-induced ternary interactions, enabling a more effective approach to structure-based optimization of Proteolysis Targeting Chimeras.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on April 5, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 22,000 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 11,000 shares of common stock and restricted stock units (“RSUs”).

Akebia Therapeutics, Inc. today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas.

Pear Therapeutics, Inc. announced that the Company and its wholly owned subsidiary, Pear Therapeutics, Inc. each voluntarily filed for protection under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code.